Johnson & Johnson JOHNSON & JOHNSON ORD (CDI)
Johnson & Johnson JOHNSON & JOHNS.../ US4781601046 /
0R34
|
26/04/2024 19:25:35
|
Chg.
-
|
Volume |
Bid26/04/2024 |
Ask26/04/2024 |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
146.60USD
|
-
|
7,448
Turnover: 86,416.47 |
-Bid Size: - |
-Ask Size: - |
374.31 bill.USD |
3.02% |
11.20 |
Business description
Johnson & Johnson and its subsidiaries (the "Company") have employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. Johnson & Johnson is a holding company, which has more than 250 operating companies conducting business in virtually all countries of the world. The Company’s primary focus is products related to human health and well-being. Johnson & Johnson was incorporated in the State of New Jersey in 1887.
Management board & Supervisory board
| CEO |
| Joaquin Duato |
| Management board |
| Joseph Wolk, Dr. Peter M. Fasolo, Dr. William N. Hait, James Swanson, Jennifer Taubert, Kathryn E. Wengel, Vanessa Broadhurst, John C. Reed, M.D., Ph.D., Liz Forminard, Tim Schmid |
| Supervisory board |
| Joaquin Duato, A. Eugene Washington, M.D., Anne M. Mulcahy, D. Scott Davis, Darius Adamczyk, Dr. Jennifer A. Doudna, Dr. Mary Beckerle, Dr. Nadja West, Hubert Joly, Marillyn A. Hewson, Mark A. Weinberger, Mark B. McClellan, Paula A. Johnson, M.D. |
Company data
| Name: |
Johnson & Johnson |
| Address: |
One Johnson & Johnson Plaza,,New Brunswick, New Jersey 08933, USA |
| Phone: |
+1-732-524-0400 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
www.jnj.com |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
Pharmaceuticals |
| End of financial year: |
31/12 |
| Free Float: |
77.97% |
| IPO date: |
24/09/1944 |
Company calendar
|
CW 48 | 26/11/2024
Record Date
|
|
CW 48 | 26/11/2024
Ex-Dividend
|
|
CW 50 | 10/12/2024
Dividend Payment
|
